7th Dec 2007 14:01
GlaxoSmithKline PLC07 December 2007 Issued - Friday 7 December 2007, London, UK - LSE Announcement GlaxoSmithKline Announces Appointments To The Board Of Directors GlaxoSmithKline plc (GSK) today announced the following executive appointmentsand changes: • Andrew Witty, CEO Designate, and Chris Viehbacher, President US Pharmaceuticals, have been appointed Executive Directors and will join the Board of the Company with effect from 31st January 2008. • Eddie Gray, currently Senior Vice President and General Manager Pharmaceuticals UK, will succeed Andrew Witty as President, Pharmaceuticals Europe for GlaxoSmithKline. Eddie will assume his new position on 1st January 2008. • David Stout, currently President of Pharmaceuticals, will leave the company in February 2008. Commenting on the changes, Sir Christopher Gent, Chairman, said: "I am verypleased that both Andrew and Chris will be joining the Board. In doing so, wehave increased the overall number of executive directors on the Board, andensured that it remains strongly aligned to GSK's strategy and operationalperformance." JP Garnier, Chief Executive Officer, said: "I would like to thank Davidsincerely for his significant contribution to GSK and for the support he hasgiven me over many years. We wish him well in his future endeavours. Andrew andI would also like to congratulate Eddie on his appointment and welcome him tothe Corporate Executive Team. We wish him every success in managing our Europeanpharmaceuticals business." GlaxoSmithKline - one of the world's leading research-based pharmaceutical andhealthcare companies - is committed to improving the quality of human life byenabling people to do more, feel better and live longer. Notes to Editors Eddie Gray: Biography Eddie Gray was appointed Senior Vice President and General Manager,Pharmaceuticals UK for GlaxoSmithKline in 2001. He is a member of thePharmaceuticals Europe Executive Team. Previously, he was Vice President &General Manager, SmithKline Beecham Pharmaceuticals, Canada, and a member ofSmithKline Beecham's Executive Management Team for North America. Eddie joined SmithKline Beecham in 1988 as National Sales Manager. He heldvarious positions in the UK company of increasing responsibility, including Headof Hospital Sales, Marketing Manager for Anti-Infective products and BusinessUnit Director for the UK Pharmaceuticals General Medicine business before movingto the US, where he assumed responsibility for Market Research for the USPharmaceuticals business. He later became Vice President & Director ofAnti-Infectives Marketing, then Vaccines Marketing in the US, before assuminghis role in Canada. Eddie serves on the Board of Management of the Association of the BritishPharmaceutical Industry (ABPI) and chairs the ABPI Economic Strategy Group. Heis an advisory board member of Opportunity Now, an organisation for employerswho are committed to creating an inclusive workplace for women; and a Trustee ofProject HOPE UK which aims to make health care available for people around theglobe, especially children. Eddie holds an honours degree in Chemistry and Management Studies from theUniversity of London, and an MBA from the Cranfield School of Management in theUK. He is married with three daughters. Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 Claire Brough (020) 8047 5502 Alice Hunt (020) 8047 5502 Joss Mathieson (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564 Sally Ferguson (020) 8047 5543 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline